Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

Haematologica

Volumn 88, Issue 3, 2003, Pages 256-259

  Rosti, Gianantonio ^a   Trabacchi, Elena ^a   Bassi, Simona ^a   Bonifazi, Francesca ^a   De Vivo, Antonio ^a   Martinelli, Giovanni ^a   Alberti, Daniele ^b   Fincato, Gianluca ^c   Saglio, Giuseppe ^d   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Novartis Pharma   (Italy)

^c Schering Plough   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib; Peginterferon

Indexed keywords

IMATINIB; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOGENETIC ANALYSIS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; POLYETHYLENE GLYCOLS; PYRIMIDINES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 20844461361     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
2. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR/ABL positive cells. Nature Med 1996;2:561-6.
3. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
4. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31-5.
5. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
6. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
7. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate/STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
8. Druker BJ, Talpaz M, Resta M, Bin Peng RN, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
9. Kantarjian HM, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
10. th Annual Meeting; May 18-21, 2002; Orlando, Florida. Proc Am Soc Clin Oncol;2002[abstract 1].
11. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
12. Hasford J, Pfirmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. J Natl Cancer Inst 1998;90:850-8.
13. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-α n 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-7.
14. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9.
15. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol 1999;17:1858-68.
16. Bonifazi F, de Vivo A, Rosti G, Tiribelli M, Russo D, Trabacchi E, et al. Chronic myeloid leukemia and interferon α: a study of complete cytogenetic responders. Blood 2001;98:3074-81.
17. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or bone marrow transplantations. Lancet 1998;352:1087-92.
18. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI 571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-505.
19. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR/ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI 571: diverse mechanisms of resistance. Blood 2000;96:1070-9.
20. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P, et al. Clinical resistance to STI 571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
21. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, et al. BCR/ABL negative primitive progenitors suitable for transplantation can be selected from bone marrow of most early chronic phase but not accelerated phase chronic myelogenous leukemia patients. Blood 1996;87:4770-9.
22. Frassoni F, Podestà M, Piaggio G, Rosti V, Pitto A, Benvenuto F, et al. Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. Br J Haematol 1999;104:538-45.
23. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
24. Gratwohl A, Baldomero H, Urbano-Ispizua A. Transplantation in chronic myeloid leukemia. Lancet 2002;359:712-3.